Trihydroxy-6h-dibenzo[b,d]pyran-6-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: Trihydroxy-6h-dibenzo[b,d]pyran-6-one
• 英文别名: 1,2,3-trihydroxybenzo[c]chromen-6-one
• 化学式: C₁₃H₈O₅
• 分子量: 244.2
• InChiKey: RGGQFQNFDPHPSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION<br/>[FR] COMPOSITIONS COMPRENANT DES UROLITHINES, ET LEURS UTILISATIONS POUR LA STIMULATION DE SÉCRÉTION D'INSULINE
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2015055736A1

  公开（公告）日：2015-04-23

  The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.

  本发明涉及一种包含乌罗利酸A、乌罗利酸B、乌罗利酸C、乌罗利酸D或其组合的组合物，用于刺激胰岛素分泌，并且涉及使用从乌罗利酸A、乌罗利酸B、乌罗利酸C、乌罗利酸D或其组合中选择的化合物，用于刺激胰岛素分泌。本发明还涉及一种包含有效量的乌罗利酸B、乌罗利酸C、乌罗利酸D或其组合的组合物，用于治疗或预防糖尿病，特别是用于治疗或预防2型糖尿病，并且涉及使用从乌罗利酸B、乌罗利酸C、乌罗利酸D或其组合中选择的化合物，用于治疗或预防糖尿病，特别是2型糖尿病。
• Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：EP2862568A1

  公开（公告）日：2015-04-22

  The present invention relates to a composition comprising an effective amount of urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, for the treatment or the prevention of diabetes mellitus.

  本发明涉及一种组合物，包括有效量的尿石素A、尿石素B、尿石素C、尿石素D或其组合，用于刺激胰岛素分泌，并且涉及从尿石素A、尿石素B、尿石素C、尿石素D或其组合中选择一种化合物，用于刺激胰岛素分泌的用途。 本发明还涉及一种组合物，包括有效量的尿石素B、尿石素C、尿石素D或其组合，用于治疗或预防糖尿病，并且涉及从尿石素B、尿石素C、尿石素D或其组合中选择一种化合物，用于治疗或预防糖尿病的用途。
• MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS
  申请人：Cellarouge Pty Ltd.

  公开号：EP2917220A1

  公开（公告）日：2015-09-16
• COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：EP3057584A1

  公开（公告）日：2016-08-24
• [EN] MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS<br/>[FR] POLYPHÉNOLS MODIFIÉS ET COMPOSITIONS DE POLYPHÉNOLS MODIFIÉS
  申请人：CELLAROUGE PTY LTD

  公开号：WO2014071438A1

  公开（公告）日：2014-05-15

  This invention relates to polyphenolic compounds, in particular ethoxylated polyphenolic compounds and the use of such compounds in disease prevention, disease treatment, and life extension in humans and animals. The invention also relates to methods of preparing ethoxylated polyphenolic compounds, and preparation of compositions comprising the compounds, including dietary supplements and foods. The inventors describe how modified C-glycosidic ellagitannins are safe, palatable and effective at medium and high doses, and produce broad and profound health outcomes in mammals.